Combination strategies in myelodysplastic syndromes

International Journal of Hematology

Volumn 95, Issue 1, 2012, Pages 26-33

  Ornstein, Moshe C ^a   Sekeres, Mikkael A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Azacitidine; Combination; Decitabine; Lenalidomide; MDS

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIANEMIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; CYCLOSPORIN A; DNA METHYLTRANSFERASE INHIBITORS; ERYTHROPOIETIN; ETANERCEPT; EZATIOSTAT; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; ROMIPLOSTIM; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; HUMAN; IMMUNOTHERAPY; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; REFRACTORY ANEMIA; THROMBOCYTOPENIC PURPURA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84857633196     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0987-4     Document Type: Conference Paper

References (57)

1. JW Vardiman J Thiele DA Arber RD Brunning MJ Borowitz A Porwit, et al. 2009 The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 937 951 19357394 10.1182/blood-2009-03-209262 1:CAS:528:DC%2BD1MXps1eit70%3D
2. P Greenberg C Cox MM LeBeau P Fenaux P Morel G Sanz, et al. 1997 International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079 2088 9058730 1:CAS:528:DyaK2sXhvVars70%3D (Pubitemid 27132124)
3. G Garcia-Manero P Fenaux 2011 Hypomethylating agents and other novel strategies in myelodysplastic syndromes J Clin Oncol 29 516 523 21220589 10.1200/JCO.2010.31.0854 1:CAS:528:DC%2BC3MXjtFCjtrY%3D
4. MA Sekeres 2010 Are we nearer to curing patients with MDS? Best Pract Res Clin Haematol 23 481 487 21130411 10.1016/j.beha.2010.09.009
5. PK Epling-Burnette AF List 2009 Advancements in the molecular pathogenesis of myelodysplastic syndrome Curr Opin Hematol 16 70 76 19468267 10.1097/MOH.0b013e3283257ac7 1:CAS:528:DC%2BD1MXntFyksrY%3D
6. Y Jiang A Dunbar LP Gondek S Mohan M Rataul C O'Keefe, et al. 2009 Aberrant DNA methylation is a dominant mechanism in MDS progression to AML Blood 113 1315 1325 18832655 10.1182/blood-2008-06-163246 1:CAS:528: DC%2BD1MXitV2ru78%3D
7. FV Rassool TJ Gaymes N Omidvar N Brady S Beurlet M Pla, et al. 2007 Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res 67 8762 8771 17875717 10.1158/0008-5472.CAN-06-4807 1:CAS:528:DC%2BD2sXhtVCit7vE (Pubitemid 47437452)
8. RS Komrokji MA Sekeres AF List 2011 Management of lower-risk myelodysplastic syndromes: the art and evidence Curr Hematol Malig Rep 6 145 153 21442178 10.1007/s11899-011-0086-x
9. E Hellstrom-Lindberg N Gulbrandsen G Lindberg T Ahlgren IM Dahl I Dybedal, et al. 2003 A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life Br J Haematol 120 1037 1046 12648074 10.1046/j.1365-2141.2003.04153.x 1:CAS:528:DC%2BD3sXjsVaksbw%3D (Pubitemid 36411563)
10. E Hellstrom-Lindberg 1995 Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies Br J Haematol 89 67 71 7833279 1:STN:280:DyaK2M7jsVKrsQ%3D%3D
11. H Kantarjian F Giles A List R Lyons MA Sekeres S Pierce, et al. 2007 The incidence and impact of thrombocytopenia in myelodysplastic syndromes Cancer 109 1705 1714 17366593 10.1002/cncr.22602 1:CAS:528:DC%2BD2sXlsF2ntbw%3D (Pubitemid 46668530)
12. JR Gonzalez-Porras I Cordoba E Such B Nomdedeu T Vallespi F Carbonell, et al. 2011 Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome Cancer 117 24 5529 5537 21638279 10.1002/cncr.26173
13. Cruz R, Galili N, Khan GS, Raza A. Thrombocytopenia predicts for poor survival in patients with lower risk myelodysplastic syndromes (MDS). Blood (ASH annual meeting abstracts). 2010;110:Abstract 4021.
14. DJ Kuter JB Bussel RM Lyons V Pullarkat TB Gernsheimer FM Senecal, et al. 2008 Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial Lancet 371 395 403 18242413 10.1016/S0140-6736(08)60203-2 1:CAS:528:DC%2BD1cXhtl2isL4%3D (Pubitemid 351181334)
15. H Kantarjian P Fenaux MA Sekeres PS Becker A Boruchov D Bowen, et al. 2010 Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia J Clin Oncol 28 437 444 20008626 10.1200/JCO.2009.24.7999 1:CAS:528:DC%2BC3cXivFartLg%3D
16. A List G Dewald J Bennett A Giagounidis A Raza E Feldman, et al. 2006 Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 1456 1465 17021321 10.1056/NEJMoa061292 1:CAS:528:DC%2BD28XhtVGgtrvO (Pubitemid 44511560)
17. P Fenaux A Giagounidis D Selleslag O Beyne-Rauzy G Mufti M Mittelman, et al. 2011 A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q Blood 118 14 3765 3776 21753188 10.1182/blood-2011-01- 330126 1:CAS:528:DC%2BC3MXhtlCgtb%2FM
18. EM Sloand CO Wu P Greenberg N Young J Barrett 2008 Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy J Clin Oncol 26 2505 2511 18413642 10.1200/JCO.2007.11.9214
19. P Fenaux GJ Mufti E Hellstrom-Lindberg V Santini C Finelli A Giagounidis, et al. 2009 Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 223 232 19230772 10.1016/S1470-2045(09)70003-8 1:CAS:528:DC%2BD1MXisFWjsbc%3D
20. H Kantarjian JP Issa CS Rosenfeld JM Bennett M Albitar J DiPersio, et al. 2006 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 1794 1803 16532500 10.1002/cncr.21792 1:CAS:528:DC%2BD28XksFCrsrk%3D
21. L Shen H Kantarjian Y Guo E Lin J Shan X Huang, et al. 2010 DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes J Clin Oncol 28 605 613 20038729 10.1200/JCO.2009.23. 4781 1:CAS:528:DC%2BC3cXisVGgtbo%3D
22. RM Lyons TM Cosgriff SS Modi RH Gersh JD Hainsworth AL Cohn, et al. 2009 Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes J Clin Oncol 27 1850 1856 19255328 10.1200/JCO.2008.17.1058 1:CAS:528:DC%2BD1MXltlSisbw%3D
23. LR Silverman EP Demakos BL Peterson AB Kornblith JC Holland R Odchimar-Reissig, et al. 2002 Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 20 2429 2440 12011120 10.1200/JCO.2002.04.117 1:CAS:528:DC%2BD38XksFakur8%3D (Pubitemid 34525728)
24. HM Kantarjian S O'Brien X Huang G Garcia-Manero F Ravandi J Cortes, et al. 2007 Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience Cancer 109 1133 1137 17315156 10.1002/cncr.22508 1:CAS:528: DC%2BD2sXkt1WmtL4%3D (Pubitemid 46435392)
25. M Lubbert S Suciu L Baila BH Ruter U Platzbecker A Giagounidis, et al. 2011 Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group J Clin Oncol 29 1987 1996 21483003 10.1200/JCO.2010.30.9245
26. HM Kantarjian FJ Giles PL Greenberg RL Paquette ES Wang JL Gabrilove, et al. 2010 Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy Blood 116 3163 3170 20631375 10.1182/blood-2010-03-274753 1:CAS:528:DC%2BC3cXhsVeisLvO
27. Greenberg P, Garcia-Manero G, Moore MR, Damon LE, Roboz GJ, Wei H, et al. Efficacy and safety of romiplostin in patients with low or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine. Blood (ASH annual meeting abstracts). 2009;114:Abstract 1769.
28. Lyons RM, Larson RA, Kosmo MA, Gandhi S, Liu D, Chernoff M, et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood (ASH annual meeting abstracts). 2009;114:Abstract 1770.
29. V Adler Z Yin SY Fuchs M Benezra L Rosario KD Tew, et al. 1999 Regulation of JNK signaling by GSTp EMBO J 18 1321 1334 10064598 10.1093/emboj/18.5.1321 1:CAS:528:DyaK1MXhvFOku7g%3D (Pubitemid 29110316)
30. Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, et al. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009;2:20.
31. Raza A, Galili N, Smith S, Godwin JE, Boccia R, Myint H, et al. Phase 2 randomized multicenter study of extended dosing schedules of oral ezatiostat HCl (Telintra), a glutathione analog prodrug GSTP1-1 inhibitor, in low to intermediate-1 risk myelodysplastic syndrome (MDS). Blood (ASH annual meeting abstracts). 2010;116:Abstract 2910.
32. JG Herman SB Baylin 2003 Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2042 2054 14627790 10.1056/NEJMra023075 1:CAS:528:DC%2BD3sXptFKmu7s%3D (Pubitemid 37448928)
33. EE Cameron KE Bachman S Myohanen JG Herman SB Baylin 1999 Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat Genet 21 103 107 9916800 10.1038/5047 1:CAS:528:DyaK1MXltlWjtA%3D%3D (Pubitemid 29036293)
34. SD Gore S Baylin E Sugar H Carraway CB Miller M Carducci, et al. 2006 Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms Cancer Res 66 6361 6369 16778214 10.1158/0008-5472.CAN-06-0080 1:CAS:528:DC%2BD28XlvVSkurc%3D
35. BD Cheson JM Bennett H Kantarjian A Pinto CA Schiffer SD Nimer, et al. 2000 Report of an international working group to standardize response criteria for myelodysplastic syndromes Blood 96 3671 3674 11090046 1:CAS:528: DC%2BD3cXosVGnt7o%3D
36. BD Cheson JM Bennett KJ Kopecky T Buchner CL Willman EH Estey, et al. 2003 Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia J Clin Oncol 21 4642 4649 14673054 10.1200/JCO.2003.04.036 (Pubitemid 46594039)
37. G Garcia-Manero HM Kantarjian B Sanchez-Gonzalez H Yang G Rosner S Verstovsek, et al. 2006 Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia Blood 108 3271 3279 16882711 10.1182/blood-2006-03-009142 1:CAS:528:DC%2BD28Xht1ahs7fK
38. Kuendgen A, Bug G, Ottmann OG, Haase D, Hildebrandt B, Habersang K, et al. Treatment of poor risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-acacytidine ad valproic acid. Blood (ASH annual meeting abstracts). 2008;112:Abstract 3639.
39. Silverman LR, Verma A, Odchimar-Reissig R, LeBlanc A, Nejfeld V, Gabrilove JL, et al. A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study of the New York Cancer Consortium. Blood (ASH annual meeting abstracts). 2008;112:Abstract 3656.
40. Garcia-Manero G, Estey E, Jabbour E, Kadia T, Estrov Z, Cortes J, et al. Phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance or presence of other comorbidities. Blood (ASH annual meeting abstracts). 2010;116:Abstract 604.
41. Garcia-Manero G, Yang A, Klimek V, Cortes J, Ravandi F, Newsome W, et al. Phase I/II study of MGCD0103, an oral istype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) Blood. 2007;110:Abstract 444.
42. L Di Croce VA Raker M Corsaro F Fazi M Fanelli M Faretta, et al. 2002 Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor Science 295 1079 1082 11834837 10.1126/science.1065173 1:CAS:528:DC%2BD38Xht1Gqsbs%3D (Pubitemid 34132239)
43. AO Soriano H Yang S Faderl Z Estrov F Giles F Ravandi, et al. 2007 Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood 110 2302 2308 17596541 10.1182/blood-2007-03-078576 1:CAS:528: DC%2BD2sXhtFCnsbzJ (Pubitemid 47523148)
44. H Yang K Hoshino B Sanchez-Gonzalez H Kantarjian G Garcia-Manero 2005 Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid Leuk Res 29 739 748 15927669 10.1016/j.leukres.2004.11.022 1:CAS:528:DC%2BD2MXltFWltLc%3D (Pubitemid 40779480)
45. Prebet T, Gore SD, Sun Z, Greenberg PL, Juckett M, Malick L, et al. Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905. Blood (ASH annual meeting abstracts). 2010;116:Abstract 601.
46. MA Sekeres AF List D Cuthbertson R Paquette R Ganetzky D Latham, et al. 2010 Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes J Clin Oncol 28 2253 2258 20354132 10.1200/JCO.2009.26.0745 1:CAS:528:DC%2BC3cXpsFSgt70%3D
47. MA Sekeres C O'Keefe AF List K Paulic M Afable 2nd R Englehaupt, et al. 2011 Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes Am J Hematol 86 102 103 21080340 10.1002/ajh.21891
48. FR Appelbaum 1999 Antibody-targeted therapy for myeloid leukemia Semin Hematol 36 2 8 10530710 1:CAS:528:DyaK1MXntFSmtrk%3D (Pubitemid 29489654)
49. I Jilani E Estey Y Huh Y Joe T Manshouri M Yared, et al. 2002 Differences in CD33 intensity between various myeloid neoplasms Am J Clin Pathol 118 560 566 12375643 10.1309/1WMW-CMXX-4WN4-T55U (Pubitemid 44698513)
50. EL Sievers RA Larson EA Stadtmauer E Estey B Lowenberg H Dombret, et al. 2001 Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 19 3244 3254 11432892 1:CAS:528:DC%2BD3MXltlShtbw%3D (Pubitemid 32591442)
51. GJ Schiller J Slack JD Hainsworth J Mason M Saleh D Rizzieri, et al. 2006 Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes J Clin Oncol 24 2456 2464 16651647 10.1200/JCO.2005.03.7903 1:CAS:528:DC%2BD28XmtVOmsbg%3D (Pubitemid 46630622)
52. N Vey A Bosly A Guerci W Feremans H Dombret F Dreyfus, et al. 2006 Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study J Clin Oncol 24 2465 2471 16651646 10.1200/JCO.2005.03.9503 1:CAS:528:DC%2BD28XmtVOmsbY%3D (Pubitemid 46630623)
53. MA Sekeres JP Maciejewski HP Erba M Afable R Englehaupt R Sobecks, et al. 2011 A phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia Cancer 117 1253 1261 20960521 10.1002/cncr.25686 1:CAS:528:DC%2BC3MXkt1alt7Y%3D
54. Borthakur G, Garcia-Manero G, Estrov Z, Konopleva M, Burger JA, Thomas D, et al. Phase 2 study of decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high-risk myelodysplastic syndrome-outcome in previously untreated patients. Blood (ASH annual meeting abstracts). 2009;114:Abstract 114.
55. C Selleri T Sato S Anderson NS Young JP Maciejewski 1995 Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death J Cell Physiol 165 538 546 7593233 10.1002/jcp.1041650312 1:CAS:528:DyaK2MXpslalsbk%3D (Pubitemid 26004311)
56. HJ Deeg J Gotlib C Beckham K Dugan L Holmberg M Schubert, et al. 2002 Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study Leukemia 16 162 164 11840280 10.1038/sj.leu.2402356 1:CAS:528:DC%2BD38XhvFGjtbg%3D (Pubitemid 34145131)
57. BL Scott A Ramakrishnan B Storer PS Becker S Petersdorf EH Estey, et al. 2010 Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept Br J Haematol 148 944 947 20064151 10.1111/j.1365-2141.2009. 08061.x 1:CAS:528:DC%2BC3cXksVKgur0%3D